Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Oncology providers familiar with the American Society of Clinical Oncology’s (ASCO) guideline on older adults with cancer are two to four times more likely to conduct a geriatric assessment on patients with cancer over the age of 65, according to the first international ASCO survey aimed at determining if and how often cancer providers are using geriatric assessments when treating older adults.
As part of its ongoing commitment to addressing inequities in cancer care and research, ASCO is launching a free educational series focused on the role of social determinants of health in cancer care and cancer outcomes. Social determinants of health include the circumstances in which people are born, live, and work, and include social, economic, and physical factors that have a direct impact on health and health care outcomes.
On October 14, 2020, the Food and Drug Administration extended the approval of pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme Corp.) for the following indications: 
The FDA released new educational materials in Spanish to help educate patients and health care providers about biosimilar medications. The agency published the Biosimilars Patient Materials webpage in Spanish  and developed a version in Spanish of the What is a Biosimilar? infographic, Biosimilars Basics infographic and the biosimilars consumer update to help educate patients and health care providers about these important types of medications used to treat conditions such as cancer, Crohn’s disease, colitis, rheumatoid arthritis, psoriasis, and more.
On October 2, 2020, the Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) as first-line treatment for adult patients with unresectable malignant pleural mesothelioma. Read more. 
In a recent statement, Monica M. Bertagnolli, MD, FACS, FASCO, Chair of the Association for Clinical Oncology (ASCO), expressed ASCO’s support for new bipartisan Senate legislation to expand access to clinical trials and improve the quality of cancer research. The CLINICAL TREATMENT Act (S.
Due to a mandatory security update, you may not be able to access if you have an outdated web browser. Click here to see if your browser will allow you to continue to access QPP after the network update. If the page cannot be displayed, it is encouraged that you update your web browser to the most current version before the end of September 2020.
The Centers for Medicare & Medicaid Services (CMS) kicked off its 2020-2021 flu season campaign with new resources to encourage people with Medicare or other CMS health care programs to get their flu shot. CMS is taking additional actions to protect the health of the nation’s seniors from the flu and its associated health complications. This is through a robust campaign aimed at people with Medicare, with a special focus on beneficiaries who experience health disparities.